Mission Statement, Vision, & Core Values of Motus GI Holdings, Inc. (MOTS)

When you look at a company like Motus GI Holdings, Inc., whose core purpose is to revolutionize colonoscopy outcomes, you have to ask: can a powerful mission overcome a challenging balance sheet?

The firm's vision to establish its Pure-Vu system as the standard of care for inpatient colonoscopies is ambitious, but the Trailing Twelve Months (TTM) financial reality as of November 2025 shows a stark contrast, with revenue at just $327.00K against a net loss of -$16.10M. Can a medical device company with such a small market capitalization-currently around $1.44K-defintely execute on a vision that requires significant capital and market penetration?

Understanding the foundational mission and values is cruical to evaluating their high-risk, high-reward strategy; so, how do these guiding principles map to the immediate need for a strategic transaction or securing near-term financing for survival?

Motus GI Holdings, Inc. (MOTS) Overview

Motus GI Holdings, Inc., founded in 2008, was a medical technology company focused on improving endoscopy outcomes, but its journey as an independent public entity concluded in 2024. The company's core business centered on the development and commercialization of the Pure-Vu System, a device designed to clear the colon during a colonoscopy, especially in cases of inadequate bowel preparation (prep). This is a big deal because a poorly prepped colon often means a missed diagnosis or a costly, delayed procedure.

The company's flagship product, the Pure-Vu System, is a U.S. FDA-cleared medical device that integrates with standard colonoscopes and gastroscopes to provide improved visualization during both lower and upper gastrointestinal (GI) procedures. Honestly, that technology is the true asset here. It solves a real problem for physicians and patients.

In a significant corporate restructuring, Motus GI Holdings, Inc. filed for Chapter 11 bankruptcy in early 2024. Subsequently, its key assets, including the Pure-Vu System technology, were acquired by CONMED Corporation for approximately $14 million through a court-supervised sale process completed in the first quarter of 2024. The former entity's last reported quarterly sales before the acquisition were minimal, reaching only $64,000 in the first quarter of 2024.

• Founded: 2008 (Predecessor entity).
• Core Product: Pure-Vu System (for intraprocedural GI cleansing).
• Acquisition Price: Approximately $14 million (by CONMED Corporation).

Pure-Vu System's Financial Performance Under New Ownership

While Motus GI Holdings, Inc. as an independent company struggled to commercialize the Pure-Vu System, its technology now contributes to the financial performance of CONMED Corporation's General Surgery segment. This acquisition immediately moved the Pure-Vu System from a micro-cap company's struggling revenue stream to a multi-billion-dollar enterprise's portfolio.

Here's the quick math: the former entity's last quarterly revenue of $64,000 is completely dwarfed by the scale of its new home. CONMED Corporation reported sales of $337.9 million for the third quarter of 2025, an increase of 6.7% year-over-year. This is the new financial context for the Pure-Vu System.

The full-year reported revenue for CONMED is now expected to be between $1.365 billion and $1.372 billion for the 2025 fiscal year. This massive revenue base provides the capital and distribution network to finally maximize the Pure-Vu System's potential in the GI endoscopy market. What this estimate hides is the specific growth of Pure-Vu, but its inclusion in a high-growth segment suggests a significant uptick from its prior performance.

Motus GI Holdings' Pure-Vu System: A Leader in Endoscopy Innovation

The Pure-Vu System's value proposition is why a company like CONMED paid $14 million for its assets, despite the independent company's financial distress. The technology addresses a critical unmet need: improving visualization during a colonoscopy when the patient's bowel prep is poor. This is defintely a leadership position in a niche but crucial area of GI endoscopy.

The system's ability to achieve adequate cleansing levels in clinical studies-often greater than 95%-is a game-changer for hospitals, potentially reducing the need for repeat procedures and lowering the overall cost of care. The Pure-Vu System is one of the few devices cleared by the FDA to help facilitate the cleansing of the GI tract during the procedure itself, which is a key differentiator in the market. This technical superiority is why the technology is a leader, even if the original company wasn't a financial one.

To be fair, the technology's success is now inextricably linked to CONMED's execution. Still, the underlying innovation is clear. You should find out more about the technology's market position and the investors who saw its potential. Exploring Motus GI Holdings, Inc. (MOTS) Investor Profile: Who's Buying and Why?

Motus GI Holdings, Inc. (MOTS) Mission Statement

You're looking for the true north of a medical technology company, and for Motus GI Holdings, Inc. (MOTS), that guiding principle is clear: to provide innovative solutions to address unmet needs in GI endoscopy, cost-effectively improving clinical outcomes that benefit patients, providers and payers worldwide. A mission statement isn't just a plaque on the wall; it's the strategic filter for every dollar spent and every product developed.

For a company that reported a net loss of $20.0 million in the year ended December 31, 2024, this mission is a high-stakes aspiration. The vision is to transform colonoscopy procedures and set a new standard in the detection of colorectal cancer and other gastrointestinal diseases. Honestly, the financial reality-including the company's Chapter 7 bankruptcy filing in May 2024-makes the mission's intent even more important to understand, as it represents the core value proposition that investors once bought into.

The company's core values, like Passion: We Are Committed to Improving Patients' Lives, are what should drive the development of their flagship product, the Pure-Vu System. That's the kind of dedication you need in medtech.

Innovative Solutions for Unmet Needs in GI Endoscopy

The first core component of the mission is all about innovation, specifically addressing a major, long-standing problem in gastroenterology: inadequate bowel preparation. This is a critical, unmet need because if the colon isn't clean, polyps can be missed, leading to repeat procedures and a higher risk of colorectal cancer (CRC). The Pure-Vu System, which is a medical device cleared by the U.S. Food and Drug Administration (FDA), is the company's answer.

The system integrates with standard colonoscopes to clear debris-fecal matter, blood, or blood clots-during the procedure itself. This is a game-changer for challenging cases, like elderly patients or those with active bleeds. The trailing twelve-month (TTM) revenue for the company was only $327K as of March 31, 2024, which shows the commercialization challenge was defintely real, but the innovation itself targets a market performing roughly 15 million colonoscopies in the U.S. every year. The need is there; the execution was the hurdle.

• Clear debris during the procedure.
• Integrate with standard colonoscopes.
• Target challenging patient populations.

Cost-Effectively Improving Clinical Outcomes

The second pillar is the commitment to better clinical outcomes and cost-efficiency. This is where the rubber meets the road for hospitals and payers. A failed colonoscopy is a costly mistake, forcing a patient to undergo a second procedure and delaying diagnosis.

The clinical data for the Pure-Vu System is compelling and directly supports this part of the mission. In multiple clinical studies, the system consistently helped physicians achieve adequate bowel cleanliness rates greater than 95%, even in patients who had poor preparation initially. In one European feasibility study, the adequate cleansing level increased dramatically from a baseline of 19.1% to 100% after using the Pure-Vu System. Here's the quick math: a higher success rate on the first try means lower costs for the healthcare system, plus it improves the diagnostic yield, which is the whole point of a screening test.

The system is designed to reduce the dependency on conventional purgative-based bowel preps, which can be difficult for patients to complete. By improving visualization, the system is expected to reduce the number of failed and repeat procedures, which lowers the overall cost of care for a patient episode. You can find more details on the operational model here: Motus GI Holdings, Inc. (MOTS): History, Ownership, Mission, How It Works & Makes Money.

Benefiting Patients, Providers, and Payers Worldwide

The final component broadens the scope to all key stakeholders. The company's mission isn't just about the patient; it's about creating a value chain that works for everyone. For patients, the benefit is earlier, more accurate diagnoses and a less burdensome prep experience.

For providers-the doctors and hospitals-the benefit is a more efficient procedure room and better clinical results. The ability to complete a procedure that otherwise would have been incomplete is a huge win for hospital efficiency. For payers, like insurance companies, the cost-effectiveness comes from reducing the need for expensive repeat procedures. The company's total revenue for 2024 was $3.4 million, a 79% increase over 2023, but still small in the grand scheme of the global GI endoscopy market. The worldwide goal is ambitious, especially considering the U.S. commercial efforts were the primary focus, but the Pure-Vu System did receive a CE Mark for Europe, with commercial activities there expected to start in 2025. That's the global aspiration, even if the financial headwinds were too strong to overcome.

Motus GI Holdings, Inc. (MOTS) Vision Statement

You're looking at the foundational documents of Motus GI Holdings, Inc. (MOTS), and as a seasoned analyst, you know the true measure of a vision isn't just the words, but the capital and execution behind them. The company's stated vision was ambitious: to transform colonoscopy procedures and set a new standard in the detection of colorectal cancer and other gastrointestinal diseases.

But here's the stark reality you must factor into your analysis: Motus GI Holdings filed for Chapter 7 bankruptcy and ceased operations in May 2024. This means the vision, while noble, was ultimately unachievable due to severe financial distress. The company's financial health-or lack thereof-overwhelmed its strategic goals. You can see the full breakdown at Breaking Down Motus GI Holdings, Inc. (MOTS) Financial Health: Key Insights for Investors.

The company's final reported numbers from the first quarter of 2024 showed a revenue of only $61,000 alongside a net loss of $5.1 million. That's a huge gap between the vision's promise and the operational reality in the months leading up to its closure.

Pioneering the Development and Adoption of Advanced Colonoscopy Technologies

The core of the Motus GI vision was pioneering technology, specifically the Pure-Vu System, a device cleared by the U.S. Food and Drug Administration (FDA) to improve visualization during both colonoscopies and upper GI endoscopies. This technology was designed to address a critical unmet need: improving visualization in approximately 20% of colonoscopies where prep is inadequate.

The Pure-Vu EVS Gen 4, cleared by the FDA in Q4 2023 for use in the upper and lower GI tract, was their latest effort to drive market adoption. The goal was to make the system easier to use and cheaper to produce, with a reported 50% reduction in the cost-of-goods and a drop in training time from hours to minutes. Still, the commercialization efforts, even with a planned start for European activities in 2025, couldn't generate the necessary revenue to sustain the business.

• Pure-Vu EVS aimed for 38% to 96% visualization improvement.
• The market opportunity included roughly 400,000 U.S. cases per year for upper GI bleeds.
• Despite the innovation, the trailing 12-month revenue as of March 31, 2024, was only $327,000.

Innovation needs capital to survive. That's the cold math.

Improving the Patient Experience During Colonoscopies

A key pillar of the vision, rooted in the Core Value of 'Passion'-committed to improving patients' lives-was enhancing the patient experience. Inadequate bowel preparation often leads to repeat procedures, which is costly, inconvenient, and stressful for the patient. The Pure-Vu System was intended to reduce this need by clearing the field of view the first time.

The company's focus was on clinical outcomes and patient comfort, a necessary component for any successful medical device. However, the financial distress reported throughout 2024, which led to the cessation of operations, shows that the commitment to the patient experience wasn't enough to overcome the operational hurdles. The company's ability to deliver on this empathetic goal was ultimately limited by its cash reserves.

Achieving Earlier and More Accurate Diagnoses

The final component of the vision ties directly into the mission of enhancing patient outcomes and improving clinical outcomes cost-effectively. By improving visualization, the Pure-Vu System was designed to help physicians detect colorectal cancer and other conditions earlier and more accurately.

For example, in upper GI bleeds, an impaired view due to blood and clots makes identifying the bleed source difficult, a condition with a mortality rate of up to 10%. The technology was meant to mitigate this risk. What this estimate hides, though, is the immense cost of market penetration and the slow uptake in a field dominated by established giants. The significant accumulated deficits and operating losses, such as a $6.1 million net loss in Q3 2023, demonstrate that the financial runway ran out before the vision could be fully realized in the market.

Motus GI Holdings, Inc. (MOTS) Core Values

You are looking for the bedrock principles of Motus GI Holdings, Inc., and the reality is that the company's core values now represent a powerful legacy following a significant corporate transition. The independent Motus GI Holdings, Inc. ceased operations after its assets, including the innovative Pure-Vu® System, were acquired by CONMED Corporation for approximately $14 million in early 2024. Still, the original values-Passion, Pride, Performance, and People-continue to guide the development and commercialization of the Pure-Vu System, which is focused on improving visualization in gastrointestinal (GI) endoscopy. This continuity is how innovative medtech survives financial distress; the product and its mission live on.

The company's core mission remains: to provide innovative solutions that address unmet needs in GI endoscopy, ultimately improving clinical outcomes and enhancing cost-efficiency for patients, providers, and payers worldwide.

Exploring Motus GI Holdings, Inc. (MOTS) Investor Profile: Who's Buying and Why?

Passion: We Are Committed to Improving Patients' Lives

This value is the engine behind the Pure-Vu System, a single-use device designed to clear the field of view during colonoscopies and upper GI endoscopies, especially in cases of inadequate bowel preparation or active bleeding. The focus is on solving a real patient problem. Clinical data shows the system's effectiveness: in studies, the Pure-Vu System achieved a 98% success rate in cleansing inadequately prepared colons, which drastically reduces the need for repeat procedures.

The latest iteration, the Pure-Vu EVS System, expanded the mission to upper GI bleeds, a high-acuity area where poor visualization is common. The technology aims to provide the necessary clarity to address emergent patients sooner, expediting diagnosis and treatment. This is not just a feature; it's a commitment to reducing the risk of a high-mortality condition. Honestly, that 98% success rate is the most important number here.

• Reduce repeat procedures and associated costs.
• Improve detection rate of polyps and other abnormalities.
• Address emergent patients with upper GI bleeds faster.

Pride: We Instill Care and Quality in All We Do

Pride in the product manifests as continuous, practical innovation. The design improvements in the Pure-Vu EVS System-the fourth generation-directly address the needs of the clinical end-user. For example, the new platform was engineered to reduce the cost-of-goods by approximately 50%, making it a more economically viable solution for hospitals. This shows a clear focus on quality that extends beyond clinical efficacy to cost-efficiency, a key driver for hospital adoption.

Here's the quick math: lower production costs help the new parent company, CONMED, offer the technology more competitively, which in turn drives broader market access for patients who need it most. Plus, the new system reduced physician and staff training requirements from hours to minutes, which is a massive quality-of-life improvement for the clinical teams using the device.

Performance: We Persevere to Deliver All of Our Commitments

The ultimate test of performance is commercial success and market reach. Despite the financial difficulties of the original entity, the Pure-Vu System's performance commitment is now integrated into the larger, more stable financial framework of CONMED Corporation. For the 2025 fiscal year, CONMED is forecasting a full-year reported revenue between $1.356 billion and $1.378 billion, with adjusted diluted earnings per share (EPS) expected in the range of $4.40 to $4.55.

This financial strength provides the necessary resources to expand the Pure-Vu System's market. The company is currently focused on commercialization in the United States, but commercial activities in Europe are expected to start in 2025, demonstrating a clear commitment to global performance and market penetration. Perseverance is about executing the long-term plan, even with a new owner.

People: We Value Our Team and Their Diversity

The value of 'People' is demonstrated through the commitment to supporting the clinical community and the internal team that transitioned during the acquisition. For customers, the company provides a robust inservice program for physicians, nurses, and technical staff, offering hands-on support to ensure they become proficient users of the system. If onboarding takes 14+ days, churn risk rises, so this support is defintely critical.

It also extends to supporting the scientific community through Investigator-Initiated Studies (IIS). The company is committed to supporting these independent, unsolicited studies that address valid scientific questions, which complements their own sponsored research and helps build a broader body of evidence for the Pure-Vu EVS System's clinical utility. This collaborative approach shows they value external expertise and diverse perspectives in advancing GI care.